These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 25110782)

  • 1. More specific CRISPR editing.
    de Souza N
    Nat Methods; 2014 Jul; 11(7):712. PubMed ID: 25110782
    [No Abstract]   [Full Text] [Related]  

  • 2. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keeping our eyes on CRISPR: the "Atlas" of gene editing.
    Wang W; Hou J; Zheng N; Wang X; Zhang J
    Cell Biol Toxicol; 2019 Aug; 35(4):285-288. PubMed ID: 31165372
    [No Abstract]   [Full Text] [Related]  

  • 4. Expanding the Biologist's Toolkit with CRISPR-Cas9.
    Sternberg SH; Doudna JA
    Mol Cell; 2015 May; 58(4):568-74. PubMed ID: 26000842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of CRISPR/Cas9 for Efficient Genome Editing in Toxoplasma gondii.
    Shen B; Brown K; Long S; Sibley LD
    Methods Mol Biol; 2017; 1498():79-103. PubMed ID: 27709570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
    Duroux-Richard I; Giovannangeli C; Apparailly F
    Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
    [No Abstract]   [Full Text] [Related]  

  • 8. Expanding the CRISPR Toolbox with ErCas12a in Zebrafish and Human Cells.
    Wierson WA; Simone BW; WareJoncas Z; Mann C; Welker JM; Kar B; Emch MJ; Friedberg I; Gendron WAC; Barry MA; Clark KJ; Dobbs DL; McGrail MA; Ekker SC; Essner JJ
    CRISPR J; 2019 Dec; 2(6):417-433. PubMed ID: 31742435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Battling CRISPR-Cas9 off-target genome editing.
    Li D; Zhou H; Zeng X
    Cell Biol Toxicol; 2019 Oct; 35(5):403-406. PubMed ID: 31313008
    [No Abstract]   [Full Text] [Related]  

  • 11. Minimizing off-target effects in CRISPR-Cas9 genome editing.
    Chen SJ
    Cell Biol Toxicol; 2019 Oct; 35(5):399-401. PubMed ID: 31317359
    [No Abstract]   [Full Text] [Related]  

  • 12. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR as a strong gene editing tool.
    Shen S; Loh TJ; Shen H; Zheng X; Shen H
    BMB Rep; 2017 Jan; 50(1):20-24. PubMed ID: 27616359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
    Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
    Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cas9 immunity creates challenges for CRISPR gene editing therapies.
    Crudele JM; Chamberlain JS
    Nat Commun; 2018 Aug; 9(1):3497. PubMed ID: 30158648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining CRISPR-based genome and epigenome editing off-targets.
    Luo Y
    Cell Biol Toxicol; 2019 Aug; 35(4):281-283. PubMed ID: 31227932
    [No Abstract]   [Full Text] [Related]  

  • 17. Cas9, Cpf1 and C2c1/2/3-What's next?
    Nakade S; Yamamoto T; Sakuma T
    Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome Editing in Retinal Diseases using CRISPR Technology.
    Yiu G
    Ophthalmol Retina; 2018 Jan; 2(1):1-3. PubMed ID: 31047294
    [No Abstract]   [Full Text] [Related]  

  • 19. CRISPR: gene editing is just the beginning.
    Ledford H
    Nature; 2016 Mar; 531(7593):156-9. PubMed ID: 26961639
    [No Abstract]   [Full Text] [Related]  

  • 20. Meeting Report: German Genetics Society-Genome Editing with CRISPR.
    Maier LK; Marchfelder A; Randau L
    Bioessays; 2020 Feb; 42(2):e1900223. PubMed ID: 31853989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.